Medicine for treating cancer
AssigneeChiome Bioscience Inc.
InventorsKoji NAKAMURA, Kota TAKAHASHI, Izumi SAKAGUCHI
Life of this patent
Estimating the term…
Abstract
The present invention provides a therapeutic agent and a therapeutic method for cancer, etc., capable of exerting a more potent and sustained antitumor effect than existing FGFR4-selective tyrosine kinase inhibitors. The present invention is directed to a pharmaceutical combination for the treatment of cancer, characterized by comprising: a substance which inhibits or suppresses the tyrosine kinase activity of fibroblast growth factor receptor 4 (FGFR4), or a prodrug thereof, or a pharmacologically acceptable salt thereof, or a hydrate or solvate thereof; and an antibody against human DLK-1, which has in vivo antitumor activity, or an antibody fragment derived from the antibody.
Claims20
A pharmaceutical combination for the treatment of cancer, comprising:
- a substance which inhibits or suppresses the tyrosine kinase activity of fibroblast growth factor receptor 4 (FGFR4), or a prodrug thereof, or a pharmacologically acceptable salt thereof, or a hydrate or solvate thereof;
- and
- an antibody against human DLK-1, which has in vivo antitumor activity, or an antibody fragment derived from the antibody.
A pharmaceutical composition for the treatment of cancer, comprising an antibody against human DLK-1, which has in vivo antitumor activity, or an antibody fragment derived from the antibody,
- wherein the pharmaceutical composition is used in combination with a substance which inhibits or suppresses the tyrosine kinase activity of fibroblast growth factor receptor 4 (FGFR4), or a prodrug thereof, or a pharmacologically acceptable salt thereof, or a hydrate or solvate thereof.
A pharmaceutical composition for the treatment of cancer, comprising a substance which inhibits or suppresses the tyrosine kinase activity of fibroblast growth factor receptor 4 (FGFR4), or a prodrug thereof, or a pharmacologically acceptable salt thereof, or a hydrate or solvate thereof,
- wherein the pharmaceutical composition is used in combination with an antibody against human DLK-1, which has in vivo antitumor activity, or an antibody fragment derived from the antibody.
A pharmaceutical composition for the treatment of cancer, comprising an antibody against human DLK-1, which has in vivo antitumor activity, or an antibody fragment derived from the antibody,
- wherein the treatment comprises administering a substance which inhibits or suppresses the tyrosine kinase activity of fibroblast growth factor receptor 4 (FGFR4), or a prodrug thereof, or a pharmacologically acceptable salt thereof, or a hydrate or solvate thereof.
A pharmaceutical composition for the treatment of cancer, comprising a substance which inhibits or suppresses the tyrosine kinase activity of fibroblast growth factor receptor 4 (FGFR4), or a prodrug thereof, or a pharmacologically acceptable salt thereof, or a hydrate or solvate thereof,
- wherein the treatment comprises administering an antibody against human DLK-1, which has in vivo antitumor activity, or an antibody fragment derived from the antibody.
(canceled)
A therapeutic method for cancer, comprising:
- administering to a subject
- a substance which inhibits or suppresses the tyrosine kinase activity of fibroblast growth factor receptor 4 (FGFR4), or a prodrug thereof, or a pharmacologically acceptable salt thereof, or a hydrate or solvate thereof;
- and
- an antibody against human DLK-1, which has in vivo antitumor activity, or an antibody fragment derived from the antibody.
A kit for the treatment of cancer, comprising:
- a substance which inhibits or suppresses the tyrosine kinase activity of fibroblast growth factor receptor 4 (FGFR4), or a prodrug thereof, or a pharmacologically acceptable salt thereof, or a hydrate or solvate thereof;
- and
- an antibody against human DLK-1, which has in vivo antitumor activity, or an antibody fragment derived from the antibody.
Dependencies are inferred from the claim text.